Tyrosine Kinases / Adaptors
| CSTコード |
包装 |
希望納入価格(円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1110 | 100 μg | 16,000 | |
|
EGFR抗体製品一覧
| 使用目的 | |
Phospho-EGF Receptor (Tyr1068)Antibody (#2234)とPhospho-EGF Receptor (Tyr1068) (D7A5) XP™ Rabbit mAb (#3777)の反応をブロックし、抗体の反応特異性を確認するために使用 |
Western Blotting
Western blot analysis of extracts from A431 cells, untreated or EGF-stimulated, using Phospho-EGF Receptor (Tyr1068) Antibody #2234 (left) or the same antibody preincubated with Phospho-EGF Receptor (Tyr1068) Antibody Blocking Peptide (right).
The epidermal growth factor (EGF) receptor is a 170 kDa transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling, internalization and lysosomal degradation (1,2). Phosphorylation of EGF receptor (EGFR) at Tyr845 in the kinase domain is implicated in stabilizing the activation loop, maintaining the active state enzyme and providing a binding surface for substrate proteins (3,4). c-Src is involved in phosphorylation of EGFR at Tyr845 (5). The SH2 domain of PLCγ binds at phospho-Tyr992, resulting in activation of PLCγ-mediated downstream signaling (6). Phosphorylation of EGFR at Tyr1045 creates a major docking site for c-Cbl, an adaptor protein that leads to receptor ubiquitination and degradation following EGFR activation (7,8). The GRB2 adaptor protein binds activated EGFR at phospho-Tyr1068 (9). A pair of phosphorylated EGFR residues (Tyr1148 and Tyr1173) provides a docking site for the Shc scaffold protein, with both sites involved in MAP kinase signaling activation (2). Phosphorylation of EGFR at specific serine and threonine residues attenuates EGFR kinase activity. EGFR carboxy-terminal residues Ser1046 and Ser1047 are phosphorylated by CaM kinase II; mutation of either of these serines results in upregulated EGFR tyrosine autophosphorylation (10).
-
Hackel, P.O. et al. (1999)
Curr Opin Cell Biol
11, 184-9.
-
Zwick, E. et al. (1999)
Trends Pharmacol Sci
20, 408-12.
-
Cooper, J.A. and Howell, B. (1993)
Cell
73, 1051-4.
-
Hubbard, S.R. et al. (1994)
Nature
372, 746-54.
-
Biscardi, J.S. et al. (1999)
J Biol Chem
274, 8335-43.
-
Emlet, D.R. et al. (1997)
J Biol Chem
272, 4079-86.
-
Levkowitz, G. et al. (1999)
Mol Cell
4, 1029-40.
-
Ettenberg, S.A. et al. (1999)
Oncogene
18, 1855-66.
-
Rojas, M. et al. (1996)
J Biol Chem
271, 27456-61.
-
Feinmesser, R.L. et al. (1999)
J Biol Chem
274, 16168-73.